Blog of Intellectual Capital

Good afternoon:

Gerbsman Partners is pleased to announce it has established a “strategic relationship” with Sinnomedical LLC, Hong Kong based Advisory firm.  Founded in 2015, Sinnomedical LLC, is an Advisory firm that specializes in M&A, crossborder tech transfer, capital raising, and strategic partnerships.  Sinnomedical has  significant transactional experience with clients in China, USA, Europe, Middle East, and Israel.  The Advisory focuses exclusively on Medical Technology, including Medical Devices, AI-driven medtech, biotech and drug-device combinations. Clients include PE firms, MNCs, VC firms, Family Offices, and China-based Incubators.

Gerbsman Partners is a Restructuring and Private Investment Banking firm that is strategically positioned to assist portfolio companies of equity investors, senior lenders and bondholders maximize enterprise value.  Since 1980, Gerbsman Partners has been involved in over $2.3 billion of restructurings, M&A and financing transactions and has maximized enterprise value for stakeholders and shareholders in over 120 companies. These were highly leveraged, under-performing, under-capitalized and under-valued companies and their Intellectual Property, as well as emerging growth companies. Together with Sinnomedical, Gerbsman Partners will extend its capabilities in the China and Middle East areas to maximize and monetize intellectual property, access to capital for US based companies, and business/financial consulting.

Mark Maciejewski, Managing Director of Sinnomedical said.  “Our partnership will enable us to lend our expertise in China and Middle East markets to provide access to capital for US based companies, as well as providing an additional distribution capability for Gerbsman Partners proprietary “Date Certain M&A Process”.   

By background, Mark has strong relationships and experience with the international venture capital and private equity community and life science companies. In 2012 to present, Mr. Maciejewski founded DiNovA Capital LL a Shenzhen and Shanghai-based Venture Capital Fund focused on Global investing in disruptive medical technologies. DiNovA has investments in Broncus Medical, Venus Medtech, Vessix, Lone Star, TruTag and Mitralyn. Both Broncus and Venus MedTech have done an IPO on the Hong Kong Stock exchange. VENUS’ market cap is over $2 Billion USD. Mr. Maciejewski also served as the senior vice president of international investments for the National Technology Enterprise Company (Division of the Kuwait Investment Authority). During his tenure at the KIA, Mr. Maciejewski managed the Medical Private Equity Division of the National Technology Enterprise Company with capital of $250 million USD.

If appropriate, Mark, Ken Hardesty (a member of Gerbsman Partners Board of Intellectual Capital) and I are available to strategize and develop action plans for maximizing and monetizing enterprise value.

Best regards

Steve Gerbsman

Steven R. Gerbsman
Principal
steve@gerbsmanpartners.com
https://gerbsmanpartners.com

Read Full Post »